Mide kanserli hastalarda adjuvan kemoradyoterapi: Tek merkez deneyimi

Background/aims: The purpose of this study was to review survival analysis, side effects and prognostic factors in patients with gastric cancer who were treated with adjuvant chemoradiotherapy. Materials and Methods: In this study, we retrospectively evaluated the data of 90 patients with gastric cancer followed at Cumhuriyet University Faculty of Medicine, Oncology Center. Results: This study analyzed the data of 90 patients (68 (76%) males, 22 (24%) females). The median follow-up was 19 months (range: 4-105). The two-year overall and disease-free survival rates were 62% and 58%, respectively. In univariate analysis, the factors that determined survival were grade (p: 0.039), T (p: 0.001) and N (p: 0.020) stages, weight loss (p: 0.001), Eastern Cooperative Oncology Group performance status (p: 0.002), anemia (p: 0.019), and hypoalbuminemia (p: 0.001). After multivariate analysis, weight loss (p: 0.008), T stage (p: 0.024) and Eastern Cooperative Oncology Group performance status (p: 0.033) were determined as indepenent prognostic factors that affect survival. The most frequent side effects were nausea and vomiting in 66 patients (73%), dyspepsia in 52 patients (58%), anemia in 45 patients (50%), neutropenia in 36 patients (40%), diarrhea in 34 patients (38%), and weight loss in 29 patients (32%). Conclusions: It was shown that the overall survival and disease-free survival in non-metastatic gastric cancer patients who received adjuvant chemoradiotherapy complied with the literature.